Research Projects
Key Projects
dHealth (2021-2026) |
The FNR-PEARL programme supporting the Digital Medicine Group will develop digital health concepts for Luxembourg through a joint research programme involving the UL, the Luxembourg Centre of Systems Biomedicine (LCSB), the Luxembourg Institute of Health (LIH), and the Centre Hospitalier de Luxembourg (CHL). Parkinson disease (PD) will serve as an optimal model disease to develop and utilise the potential of digitalisation. The novel digital health pathways will then be transferred to subsequent diseases. The emerging field of digital health technologies is the driver for digital medicine. Its success is based on an interdisciplinary understanding of digital health application development and management. To meet these challenges the Digital Medicine group will is composed of experts in the field of medicine, data science, ELSA, Health Economy, IT-engineering and Social Science. The vision of dHealth is to create a new “ecosystem of digital medicine” by developing a “digital health triangle” consisting of a) an IT-platform supported integrated healthcare model for PD, b) new patient-centred outcome parameters by wearable devices, and c) predictive data modelling for individualised patient care. Figure: Digital Health Triangle: Digital medicine and health applications require better objective outcomes provided by new patient-centred healthcare technologies that have to be integrated into the medical application knowledge, workflows and communication requirements of all stakeholders. The Digital medicine group will address the following topics:
Funding and Partner Institutions: FNR, LCSB, LIH, CHL, IT for Translational Medicine (ITTM) (Luxembourg), Portabiles HealthCare Technologies (P-HCT) (Germany), Refinio (Germany); |
DIGIPD (2021-2024) |
DIGIPD is a European funded project (ERA-PERMED (H2020)) with partners from Germany, France and Luxembourg. This DIGIPD project is validating digital biomarkers to improve individualised diagnosis and prognosis for Parkinson patients. To better predict disease progression and therefore disease management, impairment of gait, voice and face movement is measured using digital technology to adapt treatment. Depending on disease progression patients can be stratified into subgroups for clinical trials to revea new or better drugs. The project is coordinated by the Fraunhofer Institute for Algorithms and Scientific Computing SCAI. Funding and Partner Institutions: |